CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Vertex Pharmaceuticals has pulled out of a planned four-year collaboration with Verve Therapeutics, returning all rights to a preclinical gene editing program for liver disease. Verve announced the ...

Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is now approved in the United Kingdom for treating the blood disorders sickle cell disease and beta thalassemia. It’s the first ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities ...

Meanwhile, Vertex continues to expand its portfolio through the acquisition of Alpine Immune Sciences and strategic licensing deals with Affinia Therapeutics, emphasising the competitive pressure ...